Lovelace Journal Center Pediatrics is categorized under Doctors in Albuquerque, NM and active since 2005.
Lovelace Journal Center Pediatrics was established in 2005, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Doctors business, which does work in the B2C market, and is classified as a Doctors, under code number 621111 by the NAICS.
If you are seeking more information, feel free to contact Robert Matc at the company’s single location by writing to 5150 Journal Center Boulevard Ne, Albuquerque, New Mexico NM 87109 or by phoning (505) 262-3212. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Lovelace Journal Center Pediatrics |
| Contact Person: | Robert Matc |
| Address: | 5150 Journal Center Boulevard Ne, Albuquerque, New Mexico 87109 |
| Phone Number: | (505) 262-3212 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 2005 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Doctors |
| SIC Code: | 8011 |
| NAICS Code: | 621111 |
| Share This Business: |
Lovelace Journal Center Pediatrics was started in 2005 to provide professional Doctors under the SIC code 8011 and NAICS code 621111. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Robert Matc for inquiries that concern Lovelace Journal Center Pediatrics by calling the company number (505) 262-3212, as your correspondence is most welcome. Additionally, the physical location of the single location of Lovelace Journal Center Pediatrics can be found at the coordinates 35.169949,-106.58545 as well as the street address 5150 Journal Center Boulevard Ne in Albuquerque, New Mexico 87109.
For its online presence, you may visit Lovelace Journal Center Pediatrics’s website at and engage with its social media outlets through on Twitter and on Facebook.